157: C-reactive protein (CRP) as a biomarker of exacerbation presentation and treatment response

VanDevanter, Donald R.; Heltshe, Sonya L.; Skalland, M.; West, NP; Sanders, David J.; Goss, Christopher H.; Flume, Patrick A.

doi:10.1016/s1569-1993(21)01582-4

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…evaluated the correlation between CRP levels and survival time, and observed that patients with CRP levels higher than the median had a higher mortality rate; that is, higher CRP levels in the CSF were associated with a shorter survival time ( 108 ). In addition, CRP levels can be used as a valuable index to evaluate the fluctuation of the disease and to predict possible respiratory tract infections during the course of the disease ( 109 ). These studies confirmed the value of CRP as a prognostic biomarker in patients with ALS.…”

Section: Acute Phase Protein(app)mentioning

confidence: 99%

Inflammatory checkpoints in amyotrophic lateral sclerosis: From biomarkers to therapeutic targets

Jiang

Wang²,

Hao³

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by progressive motor neuron damage. Due to the complexity of the ALS, so far the etiology and underlying pathogenesis of sporadic ALS are not completely understood. Recently, many studies have emphasized the role of inflammatory networks, which are comprised of various inflammatory molecules and proteins in the pathogenesis of ALS. Inflammatory molecules and proteins may be used as independent predictors of patient survival and might be used in patient stratification and in evaluating the therapeutic response in clinical trials. This review article describes the latest advances in various inflammatory markers in ALS and its animal models. In particular, this review discusses the role of inflammatory molecule markers in the pathogenesis of the disease and their relationship with clinical parameters. We also highlight the advantages and disadvantages of applying inflammatory markers in clinical manifestations, animal studies, and drug clinical trials. Further, we summarize the potential application of some inflammatory biomarkers as new therapeutic targets and therapeutic strategies, which would perhaps expand the therapeutic interventions for ALS.

show abstract

Section: Acute Phase Protein(app)mentioning

confidence: 99%